Substance P exerts different effects when applied to the medullary respiratory network. *In vivo* microinjection of substance P into the ventrolateral medulla prolongs expiratory time and augments tidal volume \[[@B1],[@B2]\] whereas respiratory frequency is enhanced in rhythmic *in vitro* preparations of immature rat \[[@B3],[@B4]\]. Here, we microinjected substance P and an NK~1~ receptor agonist (GR73632) into the ventral respiratory group of an arterially perfused, *in situ*, working heart-brainstem preparation of mature rat\[[@B5]\]. We wished to determine (i) the effects of NK~1~ receptor activation in the ventral medullary respiratory network of this perfused preparation and (ii), the neuronal mechanism that could account for any changes in respiratory motor outflow.

Unilateral microinjection of substance P (1000 pmol) into the ventral respiratory group prolonged phrenic nerve activity cycle length from 2.0 ± 0.2--4.0 ± 0.7 s (*P* \< 0.01; *n* = 7 sites). Qualitatively a similar response was observed with GR73632 (100 pmol). At these responsive sites, CP-99,994, an NK~1~ receptor antagonist, failed to affect respiratory motor output. Recordings from the central end of the vagus nerve indicated both inspiratory and post-inspiratory discharge (ie, stageI expiratory activity) in control. Following a microinjection of substance P, post-inspiratory discharge was both augmented and prolonged. Extracellular recordings were made from 23 respiratory neurones using compound microelectrodes for pressure ejection of drugs. Substance P (10 mM) excited 66% of post-inspiratory neurones raising both the peak firing frequency and total number of action potentials per cycle by 15% and 56% respectively; both effects were prevented by antagonising NK~1~ receptors.

Our findings indicate that substance P acting on NK~1~ receptors in the ventral respiratory network promotes a prolongation of expiratory time *via* an excitatory effect on some post-inspiratory neurones.
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